Skip to main content

Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.

Hartman AK, Gorman BK, Chakraborty S, Mody DR, Schwartz MR

Publication: Arch Pathol Lab Med (2014) • Vol 138 • Page 553-8PMID: 24678687View on PubMed

Purpose

This paper investigated the effects of fixative type (CytoLyte, neutral buffered formalin, and RPMI), pretreatment protease and protocol, and slide staining system on the ability to determine human epidermal growth factor receptor 2 (Her2/neu) status by dual-color in situ hybridization (ISH) on cell blocks and investigated if Her2 status by ISH of cell blocks was concordant with that in resection specimens by immunohistochemistry (IHC).

Conclusion

Only a small percentage of slides were enumerable when stained using a Ventana BenchMark ST regardless of fixative type, protease type, or digestion duration. A significantly higher percentage of FFPE and thrombin (collected in RPMI) block sections, but not Cellient (collected in CytoLyte) block sections, were enumerable when stained using the Ventana BenchMark Ultra, but a specific protease protocol yielding optimal results was not identified. When Her2 status was ascertained by dual-ISH, it was concordant with the status determined by IHC.

Studies (1)

Purpose

This study investigated the effects of fixative type (CytoLyte, neutral buffered formalin, and RPMI), pretreatment protease and protocol, and slide staining system on the ability to determine Her2 status by ISH on cell blocks and investigated if Her2 status by ISH of cell blocks was concordant with that in resection specimens by IHC.  Cell scrapings from 18 surgical (mastectomy, lumpectomy, and a single lung wedge resection) specimens were collected in CytoLyte, 10% neutral buffered formalin, and Roswell Park Memorial Institute medium (RPMI). Specimens collected in CytoLyte were directly embedded to make Cellient blocks and sectioned at 4µm. Specimens collected in formalin were fixed for 1 h, centrifuged, and wrapped in lens paper.  Specimens in RPMI were centrifuged, mixed with plasma and thrombin, and the thrombin cell pellet was wrapped in lens paper. Thrombin and formalin-fixed cell pellets were fixed in 10% formalin for 6-48 h, embedded in paraffin, and sectioned at 4µm. The first, fifth, and tenth section of each block was H&E stained and the remaining sections were used for dual-color ISH (Her2 and Chromosome 17) with pretreatment of Cellient blocks with 2 different proteases (Protease 2 and Protease 3) for 4 min and pretreatment of all three block types with Protease 3 or 4, 12, or 20 min. Results were compared to IHC status in the surgical specimen and FISH was performed in cases where Her2 status by IHC was equivocal.

Summary of Findings

Initial FISH results stained with a Ventana BenchMark ST from nine of the specimens were enumerable in a comparable percentage of sections from Cellient (4 of 11), FFPE (2 of 13), and thrombin (4 of 11) blocks and the authors report no consistent effect of protease type or digestion duration. When stained with the Ventana BenchMark ULTRA, enumerable signals were obtained from a higher percentage of sections of FFPE and thrombin cell blocks than Cellient cell blocks (92% and 89% versus 35%, P=0.002 and P=0.02; respectively), but a specific protocol yielding optimal results was not identified.  A higher percentage of FFPE and thrombin block sections were enumerable when stained using the Ventana BenchMark Ultra rather than the Ventana BenchMark ST (P<0.001 and P<0.03, respectively), but there was no effect of slide staining system on the percentage of sections from Cellient blocks that were enumerable. When Her2 status was determinable by dual-ISH, it was concordant with the status determined by IHC.

  • Biospecimens

    TissueBreast
    CellBreast
  • Preservation Types

    FormalinOther Preservative
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    DNAFISH
    DNAIn situ hybridization
    ProteinImmunohistochemistry
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionMethod of cell acquisition
    Scraping
    Biospecimen AcquisitionMethod of tissue acquisition
    Lumpectomy
    Mastectomy
    Surgical resection
    Analyte Extraction and PurificationProtein digestion
    12 min
    20 min
    4 min
    Protease 2
    Protease 3
    In situ hybridization SpecificTechnology platform
    IHC
    Ventana BenchMark ST
    Ventana BenchMark ULTRA